INEBILIZUMAB

0 reported adverse events

Drug classes: CD19-directed Cytolytic Antibody [EPC]

These side effects are most commonly reported by patients taking INEBILIZUMAB:

# Side effect Count
See all common reactions for INEBILIZUMAB

INEBILIZUMAB is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
See all enriched reactions for INEBILIZUMAB